Overview of Bio Rise-Up Program
Starting in 2026, the Korean Ministry of Food and Drug Safety (KFDA) launches its 'Bio Rise-Up' 1:1 Personalized Regulatory Consulting system to dramatically reduce the regulatory burden on advanced biopharmaceutical developers. Moving away from fragmented after-the-fact consultations, the program represents a paradigm shift toward end-to-end accompaniment from early development through approval.
Why a Full-Lifecycle Companion Model?
Complexity of Advanced Biologics: Cell and gene therapies face rapidly evolving quality and clinical guidelines that single companies struggle to trackReducing Development Failure: About 70% of domestic biotech ventures experience 6-9 month delays at the IND stage due to data deficiency requestsGlobal Competitiveness: Achieving regulatory alignment with the FDA and EMA from the outset is essential for parallel market entryExpansion to 13 Specialist Consultants
KFDA has newly recruited 13 senior reviewers and PhD-level experts from the Advanced Biopharmaceutical Division for 2026, establishing a dedicated single-consultant model per company across all development phases. The goal is to deliver 800+ consulting sessions to 200 firms annually.
Scope and Stages of Consulting
Five-Stage Lifecycle Support
Early Development: Candidate selection, mechanism of action assessment, regulatory classificationCMC (Quality): API and drug product quality control, GMP compliance, analytical method validationNon-clinical: Safety study design, PK/toxicity evaluation, interspecies extrapolationClinical: IND submission, clinical trial design, patient recruitment, interim analysisApproval Dossier Preparation: NDA/BLA package compilation, module-by-module drafting, review responseProduct-Specific Consulting Tracks
Advanced Biologics Track: Antibodies, recombinant proteins, vaccines — biosimilar guidelines, comparability assessmentRegenerative Medicine Track: Stem cells, tissue engineering — Advanced Regenerative Bio Act compliance, long-term follow-upGene Therapy Track: AAV/lentiviral vectors, CAR-T — gene modification safety, environmental assessment, GMO regulationsEligibility and Priority Selection Strategy
Eligibility Requirements
Korean corporate entities developing advanced biopharmaceuticals (collaboration with research institutes/universities allowed)Companies with pipelines between candidate selection and pre-approval stagesPriority bonus: Innovative Pharma certification, approved regenerative medicine clinical research, documented global expansion plansApplication Schedule and Method
Year-round Application: Submitted to the Advanced Biopharmaceutical Policy Division (quarterly priority selection meetings)Pre-Application Meeting: 30-minute free pre-consultation available (development stage assessment)Online Submission: Via the 'e-Pre-Consultation' system on the Drug Safety Country portalCritical Preparation Materials
Stage-by-Stage Checklist: Candidate profile, mechanism hypothesis, competitor analysisDraft Quality Documents: Manufacturing process flow, analytical method status, stability study planIND Preparation Package: Non-clinical summary, clinical design draft, patient recruitment planPrior Regulatory Reviews: FDA Pre-IND meeting records, EMA Scientific Advice outcomes (if available)KITIM Utilization Guide
KITIM provides pre-consultation and parallel advisory services that maximize the value of the Bio Rise-Up program. Because KFDA consulting focuses on regulatory compliance, internal document preparation and strategic planning require separate expert support.
3-Stage KITIM Support Model
Pre-Application Document Advisory: Pipeline portfolio creation, regulatory adequacy diagnostics, identification of priority-selection bonus factorsStage-by-Stage Regulatory Response Roadmap: 5-year milestone planning, KFDA response scenarios, deficiency-response playbooksParallel Government R&D Funding: Concurrent application to the Multi-Ministry Advanced Bio R&D Program (~KRW 120B annually), K-Bio Vaccine Fund, and Health & Medical Technology Promotion projectsKITIM Consulting Inquiry
KITIM combines former KFDA advisors with biotech consulting experts and has supported approximately 30 bio companies annually in dual-tracking regulatory approval and R&D funding. If you need an integrated solution from Bio Rise-Up application preparation to government R&D linkage, contact KITIM. We offer a complimentary 1-hour pre-diagnostic to design a strategy tailored to your company.
